Gilead Sciences, Inc. (NASDAQ:GILD) Position Reduced by Ieq Capital LLC

Ieq Capital LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 66,660 shares of the biopharmaceutical company’s stock after selling 15,591 shares during the period. Ieq Capital LLC’s holdings in Gilead Sciences were worth $6,157,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of GILD. Global Retirement Partners LLC lifted its position in shares of Gilead Sciences by 2.2% in the fourth quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 194 shares in the last quarter. Convergence Investment Partners LLC lifted its position in shares of Gilead Sciences by 15.8% in the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company’s stock worth $6,322,000 after purchasing an additional 9,330 shares in the last quarter. Callahan Advisors LLC lifted its position in shares of Gilead Sciences by 109.3% in the fourth quarter. Callahan Advisors LLC now owns 6,540 shares of the biopharmaceutical company’s stock worth $604,000 after purchasing an additional 3,415 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its position in shares of Gilead Sciences by 47.3% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 54,300 shares of the biopharmaceutical company’s stock worth $5,016,000 after purchasing an additional 17,439 shares in the last quarter. Finally, Morton Brown Family Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $35,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.1 %

Shares of Gilead Sciences stock opened at $109.95 on Friday. The company has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.90 and a beta of 0.18. The company’s fifty day simple moving average is $95.41 and its 200-day simple moving average is $88.63. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $111.03. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.94 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is presently 832.43%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.